Tim Higenbottam

TL;DR: U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment, and is well suited to identify asthma phenotypes using the array of "omic" datasets that are at the core of this systems medicine approach.

TL;DR: The IL-17-high asthma phenotype, characterized by bronchial epithelial dysfunction and upregulated antimicrobial and inflammatory response, resembles the immunophenotype of psoriasis, including activation of the thromboxane B2 pathway, which should be considered a biomarker for this phenotype in further studies, including clinical trials targeting IL- 17.

TL;DR: Using the consensus definition of a COPD exacerbation as the starting point from which to propose a new method for quantifying the severity of the event, this approach takes into account the relationships between the symptoms that make up an exacerbation and shows that they can be used in a single continuous severity scale.

TL;DR: The FORWARD clinical trial in severe COPD patients is a comparison of extrafine beclomethasone dipropionate and formoterol in a combination inhaler with extrafineformoterol, and is expected to provide information on the ability of EXACT to detect and measure exacerbations in a large clinical trial setting.

TL;DR: In this paper, the authors use the consensus definition of a COPD exacerbation as the starting point from which to propose a new method for quantifying the severity of the event, which takes into account the relationships between the symptoms that make up an exacerbation and shows that they can be used in a single continuous severity.